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Fast and expensive (PCR) or cheap and
slow (culture)? A mathematical modelling
study to explore screening for carbapenem
resistance in UK hospitals
Gwenan M. Knight1,2* , Eleonora Dyakova3, Siddharth Mookerjee3, Frances Davies3, Eimear T. Brannigan2,3,
Jonathan A. Otter1,3 and Alison H. Holmes1,3
Abstract
Background: Enterobacteriaceae are a common cause of hospital infections. Carbapenems are a clinically effective
treatment of such infections. However, resistance is on the rise. In particular, carbapenemase-producing carbapenem-
resistant Enterobacteriaceae (CP-CRE) are increasingly common. In order to limit spread in clinical settings, screening
and isolation is being recommended, but many different screening methods are available. We aimed to compare the
impact and costs of three algorithms for detecting CP-CRE carriage.
Methods: We developed an individual-based simulation model to compare three screening algorithms using data
from a UK National Health Service (NHS) trust. The first algorithm, “Direct PCR”, was highly sensitive/specific and quick
(half a day), but expensive. The second, “Culture + PCR”, was relatively sensitive/specific but slower, requiring 2.5 days.
A third algorithm, “PHE”, repeated the “Culture + PCR” three times with an additional PCR. Scenario analysis was used
to compare several levels of CP-CRE prevalence and coverage of screening, different specialities as well as isolation
strategies. Our outcomes were (1) days that a patient with CP-CRE was not detected and hence not isolated (“days at
risk”), (2) isolation bed days, (3) total costs and (4) mean cost per CP-CRE risk day averted per year. We also explored
limited isolation bed day capacity.
Results: We found that although a Direct PCR algorithm would reduce the number of CP-CRE days at risk, the mean
cost per CP-CRE risk day averted per year was substantially higher than for a Culture + PCR algorithm. For example, in
our model of an intensive care unit, during a year with a 1.6% CP-CRE prevalence and 63% screening coverage, there
were 508 (standard deviation 15), 642 (14) and 655 (14) days at risk under screening algorithms Direct PCR, Culture + PCR
and PHE respectively, with mean costs per risk day averted of £192, £61 and £79. These results were robust to
sensitivity analyses.
Conclusions: Our results indicate that a Culture + PCR algorithm provides the optimal balance of cost and risk
days averted, at varying isolation, prevalence and screening coverage scenarios. Findings from this study will help
clinical organisations determine the optimal screening approach for CP-CRE, balancing risk and resources.
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Background
Carbapenem antibiotics are clinically effective and well
tolerated for the treatment of antibiotic-resistant
Gram-negative bacteria and hence extremely important
for tackling life-threatening infections in UK hospitals
[1]. The most common cause of blood stream infections
in England is Gram-negative bacteria, specifically
Enterobacteriaceae [2]. The number of infections with
carbapenem-resistant Enterobacteriaceae (CRE) is on the
rise [3]. These infections lead to increased morbidity,
mortality and cost [4].
Carbapenemase-producing carbapenem-resistant Entero-
bacteriaceae (CP-CRE) are effectively a sub-population of
CRE which represent a further threat, because the genes
encoding the mechanisms of resistance (a carbapenemase)
can be transferred between bacterial species and confer ele-
vated levels of resistance compared with other mechanisms
of carbapenem resistance [5, 6]. CP-CRE have shown a not-
able rise in the number of cases over the last decade in
England [7]. They were close to absent in 2006 but have
since increased to more than 2500 isolates being referred to
the national reference laboratory in 2016 [8]. Outbreaks
have also been detected in some centres [9], and others re-
port endemic CP-CRE [10]. As a result, increasing numbers
of patients have extremely limited therapy options; thus
preventive infection control practices such as active screen-
ing and single room isolation play an even more important
part in our clinical settings [11]. CP-CRE colonisation has
been shown to correlate positively with the incidence of in-
fection attributed to CP-CRE organisms, particularly in an
intensive care unit (ICU) setting [12]. There are currently
no accepted decolonisation protocols for CP-CRE organ-
isms; hence early detection of asymptomatic carriage and
isolation are key tools to prevent transmission. However,
there is insufficient data on the effectiveness or
cost-effectiveness of various CP-CRE screening algorithms.
US (Centers for Disease Control and Prevention, CDC),
European (European Centre for Disease Prevention and
Control, ECDC) and UK (Public Health England, PHE) or-
ganisations have published guidance highlighting the im-
portance of patient screening for CP-CRE in order to
identify the carriers and prevent subsequent infection and
spread [13, 14]. The European Society of Clinical Micro-
biology and Infectious Diseases (ESCMID) recommended
patient screening on admission in both endemic and epi-
demic settings as well as pre-emptive isolation in a single
room in an epidemic setting [15]. However, there are a
number of challenges associated with this, such as the
high cost of patient screening on admission, which may
not always be optimal due to the wide range of prevalence
on admission in different areas [16, 17]. Moreover, some
CP-CRE screening methods take up to 48 h to give a re-
sult. Hence, pre-emptive isolation may not be an option,
as it could result in a high number of patients being
isolated unnecessarily for a prolonged period of time [18],
nor may it be feasible given the limited availability of isola-
tion facilities.
The most common existing CP-CRE screening methods
include conventional culture-based approaches, which
have good sensitivity and specificity but take several days
to return a result [13], and molecular polymerase chain re-
action (PCR)-based methods, which are much faster, at
least as sensitive, but substantially more expensive [19].
Importantly, CRE is defined phenotypically, whereas
CP-CRE is a genotypic phenomenon most commonly
determined by means of a molecular-based test. Whilst
PCR-based methods can only detect known
carbapenemase-encoding genes that they are designed to
detect [20], culture-based methods do not detect
non-expressed genetic mechanisms [21]. This suggests
that a combination of culture- and PCR-based tests should
be used in order to detect all phenotypic resistance and
also to confirm the underlying genetic mechanisms.
Mathematical models, often used in the field of infec-
tious diseases, provide the ideal platform from which to
simulate a range of laboratory screening options to detect
CP-CRE. Their use in the field of healthcare-associated in-
fections is well documented, with previous models of
antibiotic-resistant Gram-negatives mostly focused on the
ICU [22–24] to evaluate interventions and screening algo-
rithms [25].
Our aim was to compare the impact of different cur-
rently used screening algorithms for CP-CRE using data
from Imperial College Healthcare NHS Trust (ICHNT)
using a newly designed mathematical model. By compar-
ing different scenarios, parameterised by data from a
group of London teaching hospitals, we were able to ex-
plore the predicted clinical impact and the comparative
cost of different molecular- and culture-based screening
tools. This will help to inform both ICHNT and other
hospital trusts as to which screening methods to use in
clinical settings to help combat this increasing threat.
Methods
Data
ICHNT implemented a combination of universal screen-
ing for all admissions to certain high-risk specialities and
risk factor-based screening for all other admissions in June
2015. Universal screening was implemented in the ICU,
renal, vascular and haematology in-patient wards. This
group of patients accounts for nearly half of all trust ad-
missions. We used this universal admission screening data
over a 9-month period (June 2015–March 2016) to calcu-
late the prevalence of CP-CRE carriage at admission and
screening coverage levels (Table 1). For the purpose of the
prevalence calculation, each patient was only included
once, despite the fact that most patients were screened
multiple times during their hospital stay. Length of stay
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(LoS) distributions by CRE status (no carriage vs. carriage)
were gathered for each speciality separately (Table 1 and
Additional file 1: Table S1). We assumed that those pa-
tients with colonisation due to CRE-producing carbapene-
mases (CP-CRE) or non-carbapenemase-producing CRE
(NCP-CRE) could be grouped as having the same LoS
distribution.
We used data from ICHNT to parameterise the costs
of our screening tools (Additional file 1: Table S2). We
performed an economic evaluation from the hospital
perspective, following the Consolidated Health
Economic Evaluation Reporting Standards (CHEERS)
guidelines [26]. Over the time period investigated here,
no charge was applied for additional diagnostic work
performed at PHE. The cost of one isolation bed day
was composed of a daily cost of £20.33 (£20 for gloves
and aprons, £0.33 for infectious waste stream) and a
one-off cost from stock disposal of £113 (£385 for the
ICU) incurred at the time of patient discharge [9]. The
time horizon was 1 year with no discount rate.
Diagnostic algorithms
Three diagnostic algorithms to detect CP-CRE were
compared. The first (A) is a PCR test direct from a sam-
ple swab, the second (B) represents culture followed by
carbapenemase confirmation by PCR (the current
ICHNT hospital-based protocol), and the third (C) re-
peats (B) three times, with an additional PCR performed
at the PHE national reference laboratory to confirm a
lack of CRE. All sensitivity and specificity values are pro-
vided in Table 2. The details of the first two algorithms
are shown in Fig. 1 (all algorithms are detailed in
Additional file 1: Figure S1).
In detail, (A) “Direct PCR”, is a single, in-house PCR
direct from a screening sample. It is a quick test, which
would dramatically reduce detection time by giving re-
sults within half a day. We used estimates from the lit-
erature [27] to give a sensitivity and specificity of this
test (Table 2).
The second algorithm (B) represents the current
ICHNT protocol of “Culture + PCR”. The culture part has
Table 1 Parameter table. All parameters were estimated using
ICHNT data
Parameter Description Value References and notes
CP-CRE
prevalence
at admission
ICU 1.6%
(16/1007)
Calculated from
universal screening
data of a total of
2870 patients, over
a 9-month period
Renal 1.9%
(16/858)
Vascular 0.4%
(2/541)
Haematology 1.3%
(6/464)
Coverage of
initial admission
screening
ICU 63.0%
Renal 67.0%
Vascular 48.0%
Haematology 68.0%
Number of
speciality beds
ICU 112 Sum of all wards in
each speciality as in
March 2016Renal 71
Vascular 65
Haematology 66
Length of stay
(mean/median)
ICU S 7.9/4.0 Taken from speciality
data and based on
initial screening resultCRE 15.9/10.0
Renal S 7.8/5.0
CRE 15.5/12.0
Vascular S 6.2/4.0
CRE 12.4/7.0
Haematology S 9.6/5.0
CRE 19.6/9.0
Time to result
(days)
Culture 2 For single
component test
PHE PCR 7a
PCR 0.5
(A) Direct PCR 0.5 For complete
algorithm
(B) Culture + PCR 2.5
(C) PHE 13
S patient was carrying no Enterobacteriaceae or Enterobacteriaceae susceptible
to carbapenems, CRE patient was carrying Enterobacteriaceae resistant to
carbapenems. These data come from the patients identified as carriers using the
current ICHNT screening procedure
aAccounts for the PHE workload and specimen transportation
Table 2 Details of tests used in the algorithms
Test Negative
result
Sensitivity Specificity References
and notes
Screening algorithm
(A) Direct PCR (B) Culture + PCR (C) PHE
PCR from swab S 96% 99% Tato et al., 2016 [27] x
ICHNT PCR NCP-CREa 98% 99% ICHNT data x x
Culture (1) S 89% 91% ICHNT data x x
Culture (2) NCP-CRE 100% 85% ICHNT data x x
PHE PCR NCP-CREa 100% 100% Assumed optimal x
Sensitivity is the probability that the test detects resistance given that the patient carries resistant Enterobacteriaceae. Specificity is the probability of a negative test for
resistance given that the patient does not carry resistant bacteria
aAs both of these PCR tests are on samples that have shown to be culture positive for CRE, they are classified as NCP-CRE if the PCR test for CPE is negative
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two stages: a screening swab plated onto chromogenic
media (Colorex™ mSuperCARBA™, E&O Laboratories,
Bonnybridge, UK), followed by suspicious colonies being
tested for antimicrobial susceptibility (EUCAST disc diffu-
sion). Those colonies with defined antimicrobial resistance
profiles are tested using the ICHNT in-house PCR for car-
bapenemase gene detection (Xpert® Carba-R, Cepheid
Inc., Sunnyvale, CA, USA). The genes targeted in this kit
are KPC, NDM, VIM, OXA-48 and IMP [28]. Sensitivity
and specificity values were estimated from ICHNT data
(Table 2). Each culture stage takes a day, whilst the PCR
takes half a day (Table 1, Fig. 1).
The third algorithm (C) “PHE”, is aligned with the
PHE recommendation of three sequential screens, each
separated by 48 h to test for CRE carriage. Three culture
tests, paired with ICHNT PCR, are performed across the
whole population. In addition, a confirmatory PHE PCR
test is performed for any suspicious colonies from cul-
ture. The PHE PCR was assumed to have a higher sensi-
tivity than the ICHNT PCR. As above, sensitivity and
specificity values were estimated from ICHNT data
where possible (Table 2), and algorithm C takes 6.5 days
to perform the three within-hospital screening tests, with
a further 7 days for a PCR result from PHE (Table 1). This
latter PCR test is unlikely to have an impact on our re-
sults, but it is included to reflect the current recom-
mended algorithm and, due to the increased sensitivity, it
may detect further colonisation.
Scenarios
We considered four main scenarios including a baseline
scenario parameterised to represent the ICHNT ICU with
100% screening coverage. This baseline scenario was then
modified to include (1) an ICHNT ICU with screening
coverage at < 100% (63%, the screening coverage in
2015–2016), (2) 63% screening coverage and high
CP-CRE prevalence (20%) and (3) high (20%) CP-CRE
prevalence. The high CP-CRE prevalence (20%) was used
to represent a potentially catastrophic though not unreal-
istic scenario, as 2014 European average CRE prevalence
levels were already 7.3% [29]. The corresponding preva-
lence of NCP-CRE was set at 5%, making overall CRE
prevalence 25% in the high prevalence scenarios. In Add-
itional file 1, we also provide results for the three other
high-risk specialities (renal, vascular and haematology).
Isolation strategies
We considered one main isolation strategy: (1) only
those with confirmed CP-CRE were isolated (matching
current ICHNT practice). In Additional file 1, we also
provide results for (2) isolating no one and (3) isolating
all patients with confirmed CRE (NCP- and CP-CRE).
We did not consider any pre-emptive isolation strategies.
In our main analysis, we report the number of isolation
days required, making no assumptions about adherence
to isolation policy or availability of isolation beds.
Mathematical model
We constructed a stochastic (random) individual-based
model of patients with or without CP-CRE carriage in
hospital specialities (Fig. 2). This model captured four key
parameters: (1) the rates at which patients exit the hospital
(based on ICHNT LoS data and independent of screening
status), (2) incoming CP-CRE prevalence rates, (3) time
taken for a finalised result and (4) the efficacy of the
screening tests (see screening algorithms in Table 2). The
Fig. 1 Details of the timings of the first two screening algorithms. The third screening algorithm (PHE) is shown in detail in Additional file 1: Figure S1.
It is a combination of three (B) Culture + PCR tests with a further highly accurate PHE PCR test
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model was built to consider each speciality separately,
allowing for patients to stay for an appropriate LoS and
then replacing those who exit with new patients, screened
on entry at a certain compliance level, making the special-
ity full at all times (Fig. 2).
The model was parameterised using data from ICHNT
(Table 1). A stochastic model formulation was used to
account for the small population sizes. The stochastic
parameters included within the model were (1) the
chance of being colonised with CRE (CP-CRE,
NCP-CRE or no CRE) on entry, (2) the chance of being
tested (based on screening coverage levels), (3) the
chance of being detected (using the efficacy values as a
probability) and (4) the LoS (selected with replacement
from the data distribution).
We did not include secondary transmission in this
model, as there is insufficient evidence on the levels of
transmission of Enterobacteriaceae in a clinical setting
and on the impact of isolation interventions on this
transmission. Instead, the number of “days at risk” is a
proxy for transmission level.
Simulation
All simulations were performed in R [30]. All results are
calculated from 100 runs, where one run captures the
scenario for 1 year, with a time step of half a day. Error
bars represent the standard error taken over the 100
runs. The single cost estimates were used to multiply
the mean, minimum and maximum values from the 100
model outputs to give a range.
Outcomes
Our primary outcome was the number of days at risk:
the number of days that a patient with CP-CRE is not
detected and hence not isolated.
Our secondary outcome was the total number of isola-
tion days and the number of days those without CP-CRE
were isolated (inappropriate isolation). These values
were presented as totals, which we compared to the
number of side rooms suitable for isolation at ICHNT in
2015, which totalled 60 [18, 25]. This results in a total
number of isolation bed days available a year of 3650,
6205, 9125 and 2920 for ICU, renal, haematology and
vascular specialities respectively.
Our third outcome was the total cost evaluation of
each algorithm. The fourth outcome was the mean cost
per risk day averted for patients with CP-CRE. This was
obtained by dividing the mean total direct costs of each
scenario (screening and isolation bed day costs) by the
mean number of averted risk days (i.e. number of days
that a patient with CP-CRE was isolated). At ICHNT, as
screening algorithm (B) is the current protocol, we also
calculated the average incremental cost associated with 1
additional averted risk day for screening algorithms (A)
and (C) to inform direct decision making in our setting.
Isolation bed day capacity effects
As previously outlined, there are currently a limited
number of isolation beds at ICHNT. To account for this
potential implementation barrier, we also calculated a
“days at risk (adjusted for isolation capacity)” value. In
this analysis, the isolation days that exceeded isolation
Fig. 2 Underlying model structure. Incoming prevalence varies by scenario and speciality. Here, Susceptible refers to the patient carrying no
Enterobacteriaceae or Enterobacteriaceae that are susceptible to carbapenems. As the ward is assumed to always be full, the rate at which patients
enter is equal to the exit rate, which is the inverse of the length of stay. Screening compliance is used to determine how many of the patients are
screened when they enter the speciality and during their stay (depending on the algorithm)
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capacity were added to the number of days at risk, so
“days at risk (adjusted for isolation capacity)” included
CP-CRE non-isolation because of (1) non-detection and
(2) detection but a lack of available isolation bed. For
this we assumed that isolation beds would only be used
for CP-CRE.
We also recalculated the costs per risk day averted for
patients with CP-CRE assuming that a risk day could
only be averted if there was an isolation bed available.
Sensitivity analysis
The four main scenarios (baseline ICU speciality with four
different screening coverage and CRE prevalence levels)
comprised our main sensitivity analysis. We also explored
the impact of dramatically reducing the sensitivity of PCR
to 60% to account for a change in the circulating genetic
marker encoding the carbapenemase, such as the appear-
ance of a novel or unusual carbapenemase, within the
ICU ICHNT scenario (with 63% screening coverage).
Results
Outcomes
Our primary outcome, the number of CP-CRE days at
risk in a year, was lowest for the (A) Direct PCR screen-
ing algorithm under all scenarios (Table 3, Fig. 3a).
Under the high prevalence scenario, with 63% screening
coverage, there were 5080 (standard deviation, SD of
36), 6664 (42) and 5194 (31) days at risk under the
screening algorithms (A) Direct PCR, (B) Culture + PCR
and (C) PHE respectively (Table 3, Fig. 3a). These high
levels were reduced considerably by increasing the
screening coverage to 100% (Table 3, Fig. 3a).
Our secondary outcome, the total number of isolation
bed days, was highest for the (A) Direct PCR screening
algorithm (991–11,834 across the scenarios, Table 3),
many of which were inappropriate (due to isolation of
patients without CP-CRE, i.e. many PCR false positives)
(Table 3, Fig. 3c). In the high prevalence, high screening
scenario, between 254% and 324% of the 3650 annual
ICU isolation bed days at ICHNT would be required,
simply for CP-CRE. In the ICU scenario with low preva-
lence and low screening coverage (63%), changing to (A)
Direct PCR (from (B) Culture + PCR) would increase
the percentage of the annual isolation bed days for the
ICU required for CP-CRE from 16% to 27%.
Our third outcome, the total costs associated with
each algorithm, highlights the higher cost, from the hos-
pital perspective, of (A) Direct PCR screening (Fig. 3d,
Additional file 1: Table S3) and the increasing contribu-
tion of isolation costs as prevalence increases. Note that
for (A) Direct PCR screening costs are greater than iso-
lation costs at low prevalence.
For our fourth outcome, the mean cost per risk day
averted for patients with CP-CRE per year, the pattern
was reversed (Fig. 3b). The lowest value was for our (B)
Culture + PCR algorithm (range across the four
scenarios of £48–£63) and highest for (A) Direct PCR
(£59–£198) (Table 3), despite a reduced total number of
days at risk under the latter (Fig. 3a). The main driver of
changes in this outcome was the prevalence, with the
two low prevalence scenarios resulting in high costs per
CP-CRE carrier risk day averted, i.e. one to three times
higher than in the high prevalence (20%) scenario.
The average incremental cost associated with 1
additional averted risk day for algorithms (A) and (C)
Table 3 Results table
Screening
algorithm
Scenario Outcomes
Speciality Screening
coverage
CP-CRE
prevalence
Number of
“days at risk”
Total
isolation
bed days
Total isolation bed
days of patients
without CP-CRE
Cost per
risk day
averted (£)
Average incremental
cost per additional
averted risk day (£)
(A) Direct PCR ICU 100% 1.6% 90 (4.39) 1500 (19.25) 368 (94.96) 198.45 743.56
63% 1.6% 508 (14.83) 991 (17.98) 244 (72.30) 192.18 712.38
63% 20% 5080 (36.20) 7649 (50.40) 173 (58.47) 58.18 97.10
100% 20% 918 (14.39) 11,834 (49.99) 263 (85.91) 58.69 99.57
(B) Culture +PCR 100% 1.6% 335 (9.31) 910 (17.59) 3 (5.55) 63.05 –
63% 1.6% 642 (14.06) 600 (15.84) 4 (10.01) 61.38 –
63% 20% 6664 (42.32) 5955 (38.82) 17 (20.84) 48.09 –
100% 20% 3308 (24.68) 9282 (53.2) 29 (38.32) 48.44 –
(C) PHE 100% 1.6% 221 (3.74) 1024 (19.37) 28 (31.95) 83.18 288.63
63% 1.6% 655 (14.00) 623 (17.57) 13 (18.32) 78.69 819.56
63% 20% 5194 (31.49) 7465 (45.2) 17 (21.47) 48.05 47.90
100% 20% 2309 (11.15) 10,287 (51.71) 41 (38.09) 49.68 61.23
The outcomes are given as the mean (standard deviation) from 100 simulations. The cost per risk day averted is the mean total cost divided by the mean number
of “days at risk”. Total isolation bed days shown in bold text are greater than the existing total number of isolation bed days available to the ICU at ICHNT
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against the comparison algorithm (B) was between £97
and £744 and £48 and £820 respectively (Table 3).
Isolation bed day capacity effects
The “days at risk (adjusted for isolation capacity)” value
was higher than our primary outcome only for the high
prevalence scenarios (Additional file 1: Table S4) at ~
8900. In particular, for the high prevalence, high screening
coverage scenario, taking into account the isolation bed
day capacity limits results in a 9.6 times increase in the
number of days at risk.
Using this new “days at risk (adjusted for isolation cap-
acity)” value, the new costs per risk day averted were
higher for the high prevalence scenarios, with no differ-
ence in the relative comparison between the scenarios
((B) < (C) < (A)), although the relative difference between
(B) and (C) became greater (Additional file 1: Table S4).
Other specialities
The results for the other specialities highlight the im-
portance of variance in coverage and prevalence
(Additional file 1: Figure S2 and Tables S5–S8). The vas-
cular speciality was associated with substantially lower
numbers of risk days, due to the low CP-CRE prevalence
(0.4%), whilst renal and haematology specialities showed
substantially higher numbers of days at risk than the
ICU (base case) due to higher prevalence and longer
average lengths of stay respectively. The low prevalence
of CP-CRE in the vascular speciality also had increased
costs per averted CP-CRE risk day compared to the ICU,
whilst the other specialities had similar values to those
from the ICU. The patterns of relative algorithm
performance, described for the ICU above, were robust
across these specialities.
Other isolation strategies
Isolation of all patients confirmed to carry a CRE would
result in many inappropriate isolation days (i.e. isolation
of someone without CP-CRE) under the (C) PHE algo-
rithm due to the high false positive rate resulting from
the multiple tests (Additional file 1: Figures S3–S5),
about five times higher than under the other algorithms.
With a no isolation strategy, it can be seen that there
would be approximately 1200 and 15,000 CP-CRE “at
risk” patient days under existing or high CP-CRE preva-
lence respectively (Additional file 1: Figure S5).
Sensitivity analysis
Reducing the sensitivity of our PCR to 60% to account
for a change in genetic marker results in a substantially
higher primary outcome (from ~ 500 to ~ 750 days at
risk) and increased final outcome (~ £200 vs. ~ £250)
for the (A) Direct PCR algorithm (Additional file 1:
Figure S6).
Fit to data
Our model accurately recreated the LoS distributions from
the data, providing assurance that the model was function-
ing as anticipated (Additional file 1: Figures S7–S10). For
the ICU, there were between 4000 and 5200 patients in
a b
c d 
Fig. 3 Results figure for the four ICU scenarios showing our two main outcomes: a number of days at risk and b cost per CP-CRE carrier risk day
averted. Additional outcomes of inappropriate isolation days c and total costs (£) d are also shown. Error bars in a are standard error. No error
bars are shown in b, as this is the ratio of means. Details of the errors for values in c and d are shown in Additional file 1: Figure S2. Here Cov. is
coverage of screening and Prev. the incoming prevalence of CP-CRE
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the speciality over the year. An example of how the
model captures the changing status of a patient over
time is shown in Fig. 4, matching the algorithm given
in Fig. 1.
Discussion
We estimated the number of CP-CRE days at risk to be
lowest when using our (A) Direct PCR algorithm, owing
to the rapidity of result confirmation by PCR. This
applied to all scenarios, but was most pronounced in the
scenarios with 100% screening coverage levels. However,
the false positive rate of the (A) Direct PCR algorithm
(a direct false positive rate of 1% vs. an effective false
positive of 0.01% for (B) Culture + PCR) resulted in a
higher number of inappropriate isolation days and hence
substantially higher costs per CP-CRE carrier risk day
averted and total costs for the (A) Direct PCR algorithm.
This meant that, in terms of cost per CP-CRE carrier risk
day averted, the (B) Culture + PCR algorithm performed
best.
The differences between algorithms were reduced
under scenarios with high prevalence, when the cost per
CP-CRE carrier risk day averted was similar for all three
algorithms, independently of screening prevalence. This
highlights the importance of local epidemiology on de-
termining the impact of screening algorithms. At
ICHNT, the screening coverage has risen considerably
since the study was performed (now at 96% for the ICU)
due to quality improvement work in the trust. This sug-
gests that for the ICHNT ICU setting, where CP-CRE
prevalence is low but near 100% coverage (similar to our
baseline scenario), the (A) Direct PCR algorithm would
give the smallest number of days at risk. However, the
(B) Culture + PCR algorithm would be substantially bet-
ter in terms of cost per CP-CRE carrier risk day averted.
The (C) PHE algorithm, which is basically three repeats
of the (B) Culture + PCR algorithm with an additional
high-performance PCR, performs slightly better in terms
of risk days averted than (B) Culture + PCR; however,
the cumulative costs of these repeats result in a higher
cost per CP-CRE carrier risk day averted. This is
reflected in substantial average incremental costs, sug-
gesting that the ICHNT should continue to use (B)
Culture + PCR.
The same pattern of algorithm performance is seen in
the three other ICHNT specialities considered, which
have CP-CRE prevalence on admission ranging from 0.4
to 1.9%, but different bed numbers and lengths of stay.
Data on CP-CRE admission prevalence across England
(0.1% from another London hospital in 2015 [21]) and
Europe (1.1% in a Spanish hospital in 2006–2010 [31])
are scarce, but the level is likely to lie within the range
considered here (< 8%) [29]. Thus, the cost per CP-CRE
carrier risk day averted is likely to be lowest for (B) Cul-
ture + PCR in other English settings. Only as prevalence
increases will the false positive rate of Direct PCR algo-
rithms be counterbalanced, and the use of multiple
screens or a direct-from-swab PCR have decreasing cost
per CP-CRE carrier risk day averted. This is similar to
cost-effectiveness results from the USA, where
culture-based algorithms were found to be cost-effective,
whilst PCR gave much higher costs [32].
The impact of these screening algorithms on the de-
mand for isolation bed days rapidly increases with both
Fig. 4 Example model output showing how hospital status changes over a year for patients 4225 to 4375 in one run for the ICU speciality with
the (C) PHE screening algorithm. Here each line represents a single patient, with colours showing how their hospital status changed over time.
See Additional file 1: Figure S11 for all patients
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screening coverage and CP-CRE prevalence. Isolation
beds (side rooms) are in demand for other uses than
CP-CRE, and thus even before the > 100% demand
under all the high CP-CRE (20%) prevalence scenarios is
seen, such requirements may not be available. However,
increasing screening coverage is very important in redu-
cing the number of days at risk (and hence the potential
for onward transmission). In our case, increasing screen-
ing coverage from 63 to 100% reduced the number of
days at risk by more than 50%. This, however, was only
true when we ignored the limits of the existing isolation
bed day capacity. When we included this, the number of
days at risk was similar, as the limit on the days at risk
was not screening coverage but isolation bed availability.
Thus, pairing increased screening coverage with concur-
rent isolation bed day availability should be a focus of
hospitals [25], especially as CP-CRE prevalence on ad-
mission rises. Alternatives such as nurse cohorting or in-
creased contact precautions for certain patients, instead
of speciality isolation beds, could also be employed.
Laboratory capacity should also be considered under
increased prevalence demands, as well as screening
outside of only high-risk areas, neither of which we
included here.
The rapidity of direct PCR tests or equivalent
“point-of-care” rapid diagnostic tests makes them an at-
tractive option for hospitals. However, their cost and the
impact on isolation bed day capacity cannot be ignored.
As CP-CRE prevalence increases, this cost would be re-
duced due to the lower proportion of false positives and
the rapidity of detection. Our costings include the extra
cost generated from a patient isolated following a false
positive test. We considered only existing technology;
however, future diagnostic tests for CP-CRE including
“lab on a chip” mechanisms would be rapid and highly
specific. As shown here, if these tests can improve on
the false positive detection rate of PCR, potentially by
combining phenotypic and genotypic output, then at a
low cost, these could be greatly improved algorithms, re-
ducing dramatically the number of days at risk.
The clinical impact of our results is to provide evi-
dence for hospitals to decide between screening strat-
egies for detection and isolation of CP-CRE carriers to
prevent ongoing transmission. One aspect of the screen-
ing algorithms modelled in this paper that is not cap-
tured in the outcomes that we evaluated is that the
Direct PCR algorithm would result in more rapid identi-
fication of the specific carbapenemase involved: this has
value for the rapid identification of potential clusters
and understanding short-term local epidemiological
trends. In addition, these screening results, in the identi-
fication of CP-CRE carriage, can aid in the design of
antimicrobial treatment if subsequent infection occurs
(or is present already at admission). Whilst the greatest
clinical impact would be achieved by the most rapid test,
clinical settings operate with strict budgets, and thus a
comparison such as those presented here must be made
for on-the-ground decision making.
This study’s main strength is its direct linkage to a
“real” hospital setting. This leading London teaching
hospital group, with 15,000 admissions a month and
1300 beds, provided screening coverage data, CP-CRE
prevalence by speciality and LoS data, making the mod-
elling outputs based on “real” data, rather than hypothe-
sised parameters. This makes the applicability of the
model better and supports the reliability of the results.
The main weakness of this study was that transmission
was not explicitly included in the model due to a lack of
reliable estimates for CP-CRE transmission rates.
Therefore, the effects of isolation on CPE prevalence
could not be explored, and we do not capture the indir-
ect impact of these screening algorithms. However, the
number of CP-CRE days at risk is a proxy for heightened
levels of transmission, and our comparison of screening
tests would be similar with the addition of indirect
transmission effects, although the likely impact may
change, potentially non-linearly, with increasing resist-
ance prevalence. There is likely to be considerable un-
certainty in the transmission rate from individual
patients (those isolated and not) and between settings,
making the addition of this complexity unlikely to clarify
or improve on our results. Such “colonisation” burden
proxies of transmission risk have been proposed before
[33], with analysis showing that they link directly to ac-
quisition rates of other resistant pathogens [34, 35].
Other weaknesses, in terms of modelling assumptions,
come from our assumption that those with CP-CRE and
NCP-CRE could be grouped as having the same LoS
distribution, i.e. that those with CRE have the same LoS.
Apart from CRE status, other bacterial and all host
heterogeneities were missing, such as risk factors for car-
riage. We also did not undertake a cost-effectiveness
analysis, instead looking at the overall effect of different
variables on the impact of screening algorithms. In
addition, although we explored implementation through
exploring the impact of limited numbers of isolation bed
days, we did not include further financial or technical
constraints.
There are also limitations to our cost calculations, in
particular, the specific nature of our parameterisation,
which makes the costing results specific to our setting
and does not include the variation that may be seen.
This limits the generalisability to broad conclusions
about the comparative nature of the algorithms. We also
decided to use “cost per CP-CRE carrier risk day
averted” as the main cost comparison method. As we
did not include transmission, we could not include the
cost of CP-CRE outbreaks, and instead only the proxy of
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“risk days”. In terms of clinical impact, time to detection
of CP-CRE may override this cumulative “risk day”
calculation (if we believe that transmission from a pa-
tient could saturate), but we believe that this is unlikely
due to rapid patient movement and therefore the same
ongoing transmission risk from every “risk day”. Thus
rapidity of test result may not be optimal when making
difficult value-based decisions for infection control.
The key next step for this work depends on an improved
understanding of the transmission routes and pathways
that lead to patients being carriers of CP-CRE, as well as
the length of time patients are carriers. Once this is avail-
able, adding in transmission, and the effect of isolation on
transmission, would allow for estimation of the impact on
the additional indirect effects of screening. Similarly, with
information on the quantitative impact of different risk
factors on CP-CRE carriage (e.g. by what relative increase
are those who travel abroad more likely to carry CP-CRE)
and the prevalence of these risk factors, more heterogen-
eity in the patient host population could be included.
Conclusions
In conclusion, in English settings, where CP-CPE preva-
lence is still low, we would recommend continuation of
Culture + PCR-based algorithms, despite the reduction
in days at risk if a Direct PCR algorithm were intro-
duced. The latter suffers from a higher false positivity
rate, which results in an unacceptably high cost per risk
day averted whilst CP-CRE prevalence remains low.
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